杜皮卢马布的临床效应:一种用于治疗基穆拉病的新疗法
Bing-Shiau Shang1,2,3, Chang-Hung Hsiao4, Teng-Fu Tsao2,5
1Department of Pediatrics, Chung Shan Medical University Hospital, Taichung City, Taiwan.
Immunity, inflammation and disease
|November 29, 2023
概括
杜皮卢马布为罕见的炎症性疾病 - - 基穆拉病 (KD) 提供了一个有前途的治疗方法. 这种生物有效地管理KD症状,并减少Th2通路的参与,为儿科患者提供更安全的替代方案.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 儿科 儿科 儿科
背景情况:
- 基穆拉病 (KD) 是一种罕见的慢性炎症性疾病.
- Th2免疫通路与KD病变发生有关.
- 目前的治疗方法,如类固醇和手术都有局限性,包括发育问题和高复发率,特别是在儿科病例中.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
143
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
143


